Transcript: Dr. Scott Gottlieb on "Face the Nation with Margaret Brennan," Aug. 23, 2026
CBS News · LC · trust 52/100
Updated on: August 23, 2026 / 2:51 PM EDT / CBS News
The following is the transcript of the interview with former FDA Commissioner Scott Gottlieb, who is on the boards of Pfizer and UnitedHealthCare, that aired on "Face the Nation with Margaret Brennan" on Aug. 23, 2026.
MARGARET BRENNAN: We turn now to former FDA Commissioner Dr. Scott Gottlieb. He sits on the boards of Pfizer and United Health. Welcome back to Face the Nation. There was some good news this week, and I want to have you weigh in on it. We heard about this experimental mRNA therapeutic cancer vaccine that allows people with high-risk melanoma to live longer. So it- it doesn't prevent cancer. People hear vaccine, they might think that, but rather it's a collaboration between Moderna and Merck that is an effective treatment so far. How do you understand this mRNA breakthrough?
DR. SCOTT GOTTLIEB: Yeah, this can be highly significant. This is something that we've been working on for 30 or 40 years right now, and what's changed is that we have the ability to find proteins on the surface of cancer cells that can be used to try to train the immune system to identify cancer and prevent cancer recurrence. And so, this isn't a vaccine in a traditional sense. This is a form of cancer immunotherapy. We are delivering mRNA to try to train the body on proteins that are found on the surface of cancer cells, so that you can teach the T cells in the body to spot the cancer should it recur. And what the trial demonstrated, and we don't have the full results, we have to wait for the top line results to come out, but what the trial demonstrated was that it prevents cancer recurrence, so that basically, when the body is trained on these specific antigens, the T cells can be- be able to spot the cancer if it should recur in other parts of the body. I lost sound. I apologize.
MARGARET BRENNAN: Oh, it's okay. Can you hear me now, Dr. Gottlieb? Can you hear me now? I think we're trying to fix that. Let me take a quick commercial break, and let's see if we can get this fixed so all of us can hear each other. We'll be right back.
MARGARET BRENNAN: Welcome back to Face the Nation. We have been having some technical issues, but I believe we can now once again hear Dr. Gottlieb, the former FDA commissioner, and that he can hear us. Sorry about those problems there. You can hear us?
MARGARET BRENNAN: I wanted to pick up- when we left you, you had been explaining the promising mRNA research. In terms of what the White House has said about this breakthrough, they said it vindicated HHS's decision to reduce federal funding of mRNA vaccine research, arguing the private sector can do it. What do you make of that spin?
DR. SCOTT GOTTLIEB: Yeah, look, I think that the statements from HHS pertain, in particular, to mRNA vaccines used for infectious diseases. This is different. Like I said, this is not a vaccine in a traditional sense. It's a cancer immunotherapy. I think it's a misnomer to call it a vaccine. There's a lot of different strategies that we use to try to train the immune system to identify cancer and prevent cancer recurrence right now, including CAR-T cells and other kinds of strategies that have been around for decades. And that's what this is. It happens to use mRNA to try to elicit those cancer antigens, those cancer proteins that are going to ultimately train T cells to identify cancer that might have spread distant parts of the body and weren't excised with surgery or with upfront chemotherapy, but it's not a vaccine. This is training the immune system to identify cancer to prevent recurrence.
MARGARET BRENNAN: Okay, you were the FDA commissioner at the beginning of the first Trump administration, and I know you've said to date you think the FDA has been doing a pretty good job handling these foodborne outbreaks that the country has been experiencing. HHS is pushing back pretty hard on any criticism of what's going on, saying that when it comes to recalls, they're at the lowest levels in more than a decade. Does that mean they're doing their job really well, or does that mean they're not doing their job?
DR. SCOTT GOTTLIEB: Yeah, look, I wouldn't point to recalls as a measure of whether they're doing a good job or not doing a good job. Recalls really don't comport with whether or not the overall program is effective, and I don't think the program is not being effective. I think if you look at this year, there haven't been more outbreaks than what we traditionally see, with the exception of that cyclospora outbreak, which was an extraordinary outbreak, and I think points to real problems with produce that we are sourcing from portions of Mexico, where you can't send in inspectors. The Mexicans and the U.S. can't send inspectors into those regions because they're controlled by cartels. As far as the recalls themselves, these are largely voluntary. There's only been one mandatory recall in the history of FDA. That was back in 2018. We took it when I was there. So these are voluntary recalls by companies, and there could be the fact that recalls are down because companies aren't taking recalls. It could be that recalls are down because they're not identifying outbreaks, and in fact, recalls aren't down. When you look at the actual numbers, recalls are up slightly. It's just not the- the metric I would point to to assess the overall effectiveness of the program. I think FDA has done a reasonable job this year getting on top of these outbreaks when they've been identified by CDC.
MARGARET BRENNAN: The FDA oversees roughly 20% of the U.S. economy. This is an important agency with oversight of food and drugs. The president did make a new selection. He says Dr. Heidi Overton should be the next commissioner. She's going to face some skeptics in Congress, including Republicans. Senator Bill Cassidy, who cited her lack of managerial experience, and as he put it, her active role in the nonsensical vaccine executive order makes him question…
Read the original at CBS News →
Open in TruthVane →